baona / iStockphoto.com
With legal developments in the CRISPR field ramping up this year, LSIPR examines the current international landscape and the options for parties interested in using the gene-editing technology.
Genetically modified humans are no longer in the realm of fantasy, and neither is the patenting of the technology that makes this possible.
While the well known CRISPR/Cas9 dispute between the Broad Institute of Harvard and MIT on one side, and the University of California, Berkeley (UCB) and the University of Vienna on the other, has mainly been centred in the US, the technology is used globally. Being an exciting emerging invention, more and more companies are claiming the patent rights to it.
The CRISPR dispute has been one of the biggest clashes in the life sciences industry in the past few years. But many from outside the life sciences industry might find it challenging to understand why this technology has been so important to the parties involved.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
CRISPR, Genetically modified humans, Harvard, Cas9, USPTO, Broad institute, PTAB, UCB,